Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
56.88%
Operating Margin
-43.12%
Net Margin
88.05%
Efficiency Metrics
Revenue per Expense Ratio
1.00
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
247.26%
Income Tax Rate
0.00%
EPS
0.4400000000
Balance Sheet Analysis
Current Ratio
4.45
Cash Ratio
35.77
Working Capital
$5.36M
Debt to Equity
0.68
Debt to Assets
40.46%
Equity Ratio
59.24%
Cash Flow Analysis
Operating Cash Flow Ratio
322.87%
Free Cash Flow Ratio
322.87%
CapEx to Revenue
0.00%
Dividends Paid
$32.84M
Stock Buybacks
No buybacks
Total Shareholder Returns
$32.84M
Cash Position Change
4,233.8%
Key Takeaways (2023 FY)
Maintained positive net income growth despite revenue changes
Increased R&D investment by 100.00%
Detailed Growth Metrics
Core Performance
Revenue
111.94%
Net Income
110.36%
EPS
110.45%
Operating Income
94.54%
Operational Efficiency
R&D Expenses
100.00%
SG&A Expenses
-3.15%
Operating Cash Flow
33.76%
Free Cash Flow
33.76%
Balance Sheet Health
Assets
-3.32%
Debt
0.00%
Book Value per Share
-5.58%
Inventory
0.00%
Shareholder Returns
Dividends per Share
-4.82%
Shares Outstanding
0.00%
Long Term Trends
3Y Revenue/Share
-77.55%
5Y Revenue/Share
135.02%
3Y Dividend/Share
-11.00%
5Y Dividend/Share
-10.69%